Indoco Remedies Ltd

Indoco Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Indoco Remedies Ltd

₹ 244 0.39%
23 May - close price
indoco.com BSE: 532612 NSE: INDOCO
About

Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]

Key Points

Business Segments
A) Domestic Formulations (48% of FY24 revenue)[1]
Indoco Remedies Ltd holds a strong foothold across various therapeutic categories, including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional Products, Cardiology, Metabolic Disorders, and Primary Care medicines. In FY24, the domestic business crossed 1,280 Cr, ranking 31st in India (IQVIA MAT 2023-24). The company enjoys prescription patronage from over 240,000 prescribers, with 106 million prescriptions annually, and ranks 22nd in the Indian Pharmaceutical Market (IQVIA). It has 45 products ranking among the top 5 in their respective sub-segments.

Website BSE NSE
  • Market Cap ₹ 2,247 Cr.
  • Current Price ₹ 244
  • High / Low ₹ 388 / 190
  • Stock P/E
  • Book Value ₹ 111
  • Dividend Yield 0.62 %
  • ROCE -0.48 %
  • ROE -7.00 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 8.51% over past five years.
  • Company has a low return on equity of 5.08% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
409 408 433 399 428 426 482 459 450 431 433 411 390
329 337 345 337 363 365 410 397 401 384 392 399 391
Operating Profit 81 71 88 62 65 61 71 63 49 48 40 12 -1
OPM % 20% 18% 20% 16% 15% 14% 15% 14% 11% 11% 9% 3% -0%
0 1 0 0 0 0 4 -6 22 1 2 2 2
Interest 3 4 5 7 9 8 8 10 12 14 18 16 18
Depreciation 18 20 16 17 18 20 21 24 26 28 29 29 29
Profit before tax 60 48 67 38 39 34 46 23 33 7 -5 -31 -46
Tax % 32% 20% 26% 26% 34% 29% 24% 31% 33% 74% 107% -8% -9%
40 39 50 28 26 24 35 16 22 2 -10 -28 -41
EPS in Rs 4.39 4.19 5.40 3.05 2.80 2.65 3.81 1.77 2.46 0.28 -1.04 -2.86 -4.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
731 854 1,005 1,071 1,041 968 1,107 1,242 1,541 1,669 1,817 1,665
610 689 834 914 906 892 983 1,017 1,213 1,381 1,572 1,566
Operating Profit 120 166 171 157 135 77 123 225 328 288 245 99
OPM % 16% 19% 17% 15% 13% 8% 11% 18% 21% 17% 13% 6%
2 2 1 4 5 6 2 3 2 1 20 6
Interest 19 11 12 6 24 21 26 22 14 25 38 66
Depreciation 31 47 61 63 68 72 71 73 79 71 92 114
Profit before tax 72 110 99 91 48 -9 29 132 237 193 136 -74
Tax % 20% 24% 17% 15% 15% -69% 16% 30% 35% 26% 29% 5%
58 83 82 77 41 -3 24 93 155 142 97 -78
EPS in Rs 6.29 8.99 8.89 8.36 4.47 -0.31 2.62 10.10 16.80 15.44 10.68 -7.99
Dividend Payout % 22% 18% 18% 19% 22% -95% 11% 15% 13% 15% 14% -2%
Compounded Sales Growth
10 Years: 7%
5 Years: 9%
3 Years: 3%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -184%
Stock Price CAGR
10 Years: -5%
5 Years: 3%
3 Years: -12%
1 Year: -22%
Return on Equity
10 Years: 8%
5 Years: 9%
3 Years: 5%
Last Year: -7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 18 18 18 18 18 18 18 18
Reserves 439 500 558 633 657 642 661 751 886 1,010 1,091 1,004
92 97 140 280 282 296 262 267 257 333 672 994
180 230 224 266 281 301 330 279 325 297 363 414
Total Liabilities 729 846 941 1,197 1,238 1,258 1,272 1,315 1,486 1,658 2,145 2,430
325 340 374 440 489 468 590 570 555 678 954 1,041
CWIP 44 63 55 91 136 185 51 68 122 114 125 276
Investments 0 0 16 0 0 0 0 0 0 2 9 1
360 443 496 666 613 605 631 677 809 864 1,057 1,111
Total Assets 729 846 941 1,197 1,238 1,258 1,272 1,315 1,486 1,658 2,145 2,430

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
99 109 112 89 123 132 123 82 174 179 157 94
-41 -88 -111 -171 -135 -104 -56 -67 -121 -208 -433 -339
-59 -20 -2 132 -39 -16 -64 -30 -44 23 280 241
Net Cash Flow -1 1 -0 50 -51 12 3 -14 8 -7 4 -4

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 69 66 69 74 73 74 69 69 70 77 82 77
Inventory Days 148 181 174 189 203 209 230 245 248 228 230 307
Days Payable 95 146 137 166 157 195 183 117 107 86 100 152
Cash Conversion Cycle 122 102 105 97 119 88 116 197 212 219 212 232
Working Capital Days 73 78 80 81 77 64 57 107 113 120 124 138
ROCE % 17% 21% 17% 12% 7% 1% 6% 16% 23% 17% 10% -0%

Shareholding Pattern

Numbers in percentages

13 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
58.69% 58.68% 58.68% 58.69% 58.73% 58.75% 58.75% 58.72% 58.76% 58.76% 58.80% 58.90%
1.17% 1.19% 1.23% 1.55% 1.58% 1.59% 1.69% 1.92% 1.48% 1.70% 1.25% 1.24%
18.07% 17.97% 18.07% 18.06% 17.93% 17.79% 19.56% 19.41% 18.67% 18.25% 18.91% 18.75%
22.07% 22.16% 22.00% 21.69% 21.75% 21.87% 20.00% 19.92% 21.07% 21.27% 21.02% 21.02%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.03% 0.03% 0.09%
No. of Shareholders 38,49838,07235,71334,73135,43136,58832,60033,20134,51134,41634,67634,497

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls